Travecta Therapeutics Announces It Has Closed Its Oversubscribed Series A Round At $27 Million

June 11, 2020

Travecta Therapeutics Announces it has Closed its Oversubscribed Series A Round at $27 Million

By Philippe Mendiharat

Related Stories

    Sgi News 02

    SPRIM Global Investments names Susan Dallabrida as Chief Executive Officer of SPRIM Consultancy

    NEW YORK – February 8, 2022 – SPRIM Global Investments announces the promotion of Susan Dallabrida, PhD, to Chief Executive Officer of SPRIM Consultancy. In her nearly 2 years with SPRIM, Susan has brought both scientific and commercial leadership to the business, boosting revenue while strengthening the company’s skill sets in clinical science and innovation. In…

    Read More
    Post Hero

    BAC and Blade Announce Definitive Merger Agreement

    Proposed merger to create publicly traded biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases….

    Read More
    Sgi Portfolio Logo Aumbiosciences

    AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies

    SINGAPORE and NEW YORK, October 12, 2021 – AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging what many consider as the undruggable targets, as well as addressing the need to delay and overcome resistance to…

    Read More
    Leveraging Next Gen Tools In Rare Disease Research

    Leveraging Next-Gen Tools in Rare Disease Research

    The capture of high-quality, accurate and complete datasets in a clinical trial is always of utmost importance. But the stakes could not be higher when it comes to rare disease. It is estimated that there are over 6,000 rare diseases globally. Of that, roughly 300 million people are currently affected with a rare disease today….

    Read More
    Sgi Portfolio Logo Fibronostics

    Fibronostics Raises $8 Million in Series A Financing

    NEW YORK & SINGAPORE – August 24, 2020 – Fibronostics, a global company providing non-invasive, algorithmic diagnostics for NASH patients, announced today that it has secured $8 million in series A funding. The financing round was led by AT Capital, a leading private investment firm in Asia and, an early-stage deep-tech VC fund. This funding…

    Read More
    The Critical Need For Virtual Covid 19 Clinical Trials And Patient Training

    The Critical Need for Virtual COVID-19 Clinical Trials and Patient Training

    The FDA recently released new guidance on drug development for the prevention and treatment of COVID-19, emphasizing the need for flexible trial designs, diverse patient populations and mechanisms to ensure data accuracy. Digital components that empower decentralized recruitment, e-consent, symptoms/adverse events monitoring, wearable data capture, and telehealth visits could provide researchers with a path forward to ensure…

    Read More
    Obviohealth And Hôpital Paris Saint Joseph Announce Partnership To Track Covid 19 In Oncology Patients

    ObvioHealth and Hôpital Paris Saint-Joseph Announce Partnership to Track COVID-19 in Oncology Patients

    PARIS — June 18, 2020 – ObvioHealth, a full-service virtual research organization (VROTM), announces today a partnership with La Foundation Hôpital Paris Saint Joseph to monitor COVID-19 prevalence and symptoms among the oncology patients of the Groupe Hospitalier Paris Saint Joseph. Participants will use Obvio-19, a proprietary mobile application and digital platform built by ObvioHealth,…

    Read More
    Sprim Partners With Health Catalyst To Analyze Covid 19 Impact On Nash And Nafld

    SPRIM Partners with Health Catalyst to Analyze COVID-19 Impact on NASH and NAFLD

    SPRIM and Health Catalyst partner to jumpstart understanding of COVID-19 impact on NASH and NAFLD population to advance clinical trials for liver disease. As the coronavirus pandemic continues to sweep across the globe, new concerns arise every day about the effect of COVID-19 on a patient’s long-term health. Among those emerging concerns is the association…

    Read More
    Sgi Portfolio Logo Obviohealth

    ObvioHealth Secures $17 Million in Latest Investment Round

    SINGAPORE and NEW YORK – May 20, 2020 – ObvioHealth, a leading virtual health research organization or VROTM, announced today it has raised $17 million in its latest round of financing. This round of financing comes on the heels of a global alliance with a strategic partner announced in March. This milestone occurs at a critical time in…

    Read More
    Sgi Portfolio Logo Travecta

    Travecta Therapeutics Secures $15 Million in Financing

    NEW YORK and SINGAPORE – May 12, 2020 – Travecta Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier, announces today it has secured US$15 million in its Series A round of financing, led by TKS1, a life science focused venture capital fund formed by the partnership between SPRIM and…

    Read More